Here are Steven’s Poster Picks for Thursday, May 9, 2019:

Multiple sclerosis

1. MRI predictors of disability (P5.2-001)
2. Biomarkers: NfL and GFAP (P5.2-006, P5.2-007, P5.2-017, P5.2-021); OCBs (P5.2-014, P5.2-022)
3. Lymphocyte kinetics: and alemtuzumab (P5.2-009)
4. CIS and immune phenotype (P5.2-018)
5. Sexual dysfunction (P5.2-089)
6. Cannabis: in BC (P5.2-092), and spasticity (P5.2-100, P5.2-106)

Read More

Here are Steven’s Poster Picks for Wednesday, May 8, 2019:

Multiple sclerosis

1. Pregnancy: use of natalizumab (P4.2-093, P4.2-105), anti-CD20 therapies (P4.2-094), DMF (P4.2-095), outcomes with DMT exposure (P4.2-100), NfL levels (P4.2-092)
2. Pediatric: OCBs (P4.2-104), cognitive impairment (P4.6-035)
3. JCV Ab index (P4.2-009, P4.2-040)
4. Rare adverse events – case reports: Ocrelizumab (P4.2-010), fingolimod (P4.2-011, P4.2-012, P4.2-016, P4.2-036), cladribine (P4.2-022), alemtuzumab (P4.2-027)
5. Pharmacogenetics and cladribine (P4.2.044)

Read More

Here are Steven’s Poster Picks for Tuesday, May 7, 2019:

Multiple sclerosis

1. Progressive MS: Siponimod (P3.2-051), ocrelizumab (P3.2-031, P3.2-042), biotin (P3.2-038, P3.2-043, P3.2-063), ibudilast (P3.2-049)
2. Neurofilament-light and DMTs: Fingolimod (P3.2-032), alemtuzumab (P3.2-045), ibudilast (P3.2-033), SCT (P3.2-039)
3. Long-term data: DMF (P3.2-084), alemtuzumab (P3.2-037, P3.2-067), ocrelizumab (P3.2-054), IFNb-1b (P3.2-080), PEG-IFN-1a (P3.2-082)
4. Sequencing studies (P3.2-050, P3.2-056, P3.2-070, P3.2-075, P3.2-103)
5. Brain atrophy: DMF (P3.2-064)
6. Real-world studies: DMF (P3.2-081)
7. Clinical tips: Steroid resistance (P3.2-089)

Read More

Here are Steven’s Poster Picks for Monday, May 6, 2019:

Migraine

1. Long-term data for frenezumab (P2.10-002, P2.10-008, P2.10-015) and galcanezumab (P2.10-010)
2. Safety of ubrogepant (P2.10-003, P2.10-009)

Read More